The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus

被引:10
|
作者
Whitney, JB
Oliveira, M
Detorio, M
Guan, YJ
Wainberg, MA
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, AIDS Ctr, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
关键词
D O I
10.1128/JVI.76.17.8958-8962.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We previously constructed a series of simian immunodeficiency virus (SIV) mutants containing deletions within a 97-nucleotide region of the SIVmac239 untranslated region or leader sequence. However, as is common with live attenuated viruses, several of the mutants exhibited a moderate propensity for reversion. Since the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase is associated with diminished fitness as well as lamivudine resistance, we introduced this substitution into several of our deletion mutants to determine its effects on viral replication and compensatory reversion. Our results indicate that M184V impaired viral fitness in pair-wise comparisons of mutants that contained or lacked this substitution. We also observed that M184V significantly impaired the potential for both compensatory mutagenesis and reversion in these mutants both in cell lines and in peripheral blood mononuclear cells.
引用
收藏
页码:8958 / 8962
页数:5
相关论文
共 50 条
  • [21] Isolation and characterization of simian immunodeficiency virus variants that are resistant to nonnucleoside reverse transcriptase inhibitors
    Y. Isaka
    S. Miki
    S. Kawauchi
    A. Suyama
    H. Sugimoto
    A. Adachi
    M. Hayami
    O. Yoshie
    T. Fujiwara
    A. Sato
    Archives of Virology, 2000, 145 : 2481 - 2492
  • [22] Isolation and characterization of simian immunodeficiency virus variants that are resistant to nonnucleoside reverse transcriptase inhibitors
    Isaka, Y
    Miki, S
    Kawauchi, S
    Suyama, A
    Sugimoto, H
    Adachi, A
    Hayami, M
    Yoshie, O
    Fujiwara, T
    Sato, A
    ARCHIVES OF VIROLOGY, 2000, 145 (12) : 2481 - 2492
  • [23] Decreased rates of transmission of drug-resistant HIV-1 strains containing the M184V mutation in reverse transcriptase
    Turner, D
    Brenner, BG
    Routy, JP
    Moisi, D
    Wainberg, MA
    ANTIVIRAL THERAPY, 2003, 8 (03) : U123 - U124
  • [24] The influence of 3TC-resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency
    Hamburgh, ME
    Drosopoulos, WC
    Prasad, VR
    NUCLEIC ACIDS RESEARCH, 1998, 26 (19) : 4389 - 4394
  • [25] The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates
    Diallo, K
    Brenner, B
    Oliveira, M
    Moisi, D
    Detorio, M
    Götte, M
    Wainberg, MA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2376 - 2379
  • [26] Effect of didanosine, zalcitabine and abacavir on lamivudine resistant virus with the M184V mutation
    Verhofstede, C
    Van Wanzeele, F
    Van Der Gucht, B
    De Cabooter, N
    Demecheleer, E
    Plum, J
    AIDS, 2000, 14 : S112 - S112
  • [27] Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors
    Catucci, M
    Venturi, G
    Romano, L
    Riccio, ML
    De Milito, A
    Valensin, PE
    Zazzi, M
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 203 - 208
  • [28] Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient
    Jakobsen, Martin R.
    Arildsen, Hanne
    Krarup, Henrik B.
    Tolstrup, Martin
    Ostergaard, Lars
    Laursen, Alex L.
    CLINICAL INFECTIOUS DISEASES, 2008, 46 (09) : E88 - E91
  • [29] The impact of the HIV reverse transcriptase M184V mutation in combination with single thymidine analogue mutations on nucleoside reverse transcriptase inhibitor resistance in clinical samples from a large patient database
    Ross, L
    Parkin, N
    Bates, M
    Fisher, R
    St Clair, M
    Tisdale, M
    Lanier, R
    ANTIVIRAL THERAPY, 2003, 8 (03) : U134 - U135
  • [30] In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine
    Paredes, Roger
    Sagar, Manish
    Marconi, Vincent C.
    Hoh, Rebecca
    Martin, Jeffrey N.
    Parkin, Neil T.
    Petropoulos, Christos J.
    Deeks, Steven G.
    Kuritzkes, Daniel R.
    JOURNAL OF VIROLOGY, 2009, 83 (04) : 2038 - 2043